166 related articles for article (PubMed ID: 35220308)
1. Long-Acting Growth Hormone Preparations and Their Use in Children with Growth Hormone Deficiency.
Pampanini V; Deodati A; Inzaghi E; Cianfarani S
Horm Res Paediatr; 2023; 96(6):553-559. PubMed ID: 35220308
[TBL] [Abstract][Full Text] [Related]
2. Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs.
Yuen KCJ; Miller BS; Boguszewski CL; Hoffman AR
Front Endocrinol (Lausanne); 2021; 12():637209. PubMed ID: 33716988
[TBL] [Abstract][Full Text] [Related]
3. Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk.
Boguszewski CL
Best Pract Res Clin Endocrinol Metab; 2023 Dec; 37(6):101817. PubMed ID: 37643936
[TBL] [Abstract][Full Text] [Related]
4. Long-Acting Growth Hormone Preparations - Current Status and Future Considerations.
Miller BS; Velazquez E; Yuen KCJ
J Clin Endocrinol Metab; 2020 Jun; 105(6):e2121-33. PubMed ID: 31676901
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis.
Mameli C; Orso M; Calcaterra V; Wasniewska MG; Aversa T; Granato S; Bruschini P; Guadagni L; d'Angela D; Spandonaro F; Polistena B; Zuccotti G
Pharmacol Res; 2023 Jul; 193():106805. PubMed ID: 37236413
[TBL] [Abstract][Full Text] [Related]
6. Comparing treatment with daily and long-acting growth hormone formulations in adults with growth hormone deficiency: Challenging issues, benefits, and risks.
Höybye C
Best Pract Res Clin Endocrinol Metab; 2023 Dec; 37(6):101788. PubMed ID: 37308376
[TBL] [Abstract][Full Text] [Related]
7. Reduced Effectiveness and Comparable Safety in Biweekly
Sun C; Lu B; Liu Y; Zhang Y; Wei H; Hu X; Hu P; Zhao Q; Liu Y; Ye K; Wang K; Gu Z; Liu Z; Ye J; Zhang H; Zhu H; Jiang Z; Liu Y; Wan N; Yan C; Yin J; Ying L; Huang F; Yin Q; Xi L; Luo F; Cheng R
Front Endocrinol (Lausanne); 2021; 12():779365. PubMed ID: 34899612
[TBL] [Abstract][Full Text] [Related]
8. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE.
Yuen KCJ; Biller BMK; Radovick S; Carmichael JD; Jasim S; Pantalone KM; Hoffman AR
Endocr Pract; 2019 Nov; 25(11):1191-1232. PubMed ID: 31760824
[No Abstract] [Full Text] [Related]
9. Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients.
Miller BS; Yuen KCJ
Drug Des Devel Ther; 2022; 16():2055-2066. PubMed ID: 35791404
[TBL] [Abstract][Full Text] [Related]
10. Update on the use of long-acting growth hormone in children.
Boguszewski MCDS; Boguszewski CL
Curr Opin Pediatr; 2024 Aug; 36(4):437-441. PubMed ID: 38747211
[TBL] [Abstract][Full Text] [Related]
11. What do we do now that the long-acting growth hormone is here?
Miller BS
Front Endocrinol (Lausanne); 2022; 13():980979. PubMed ID: 36072938
[TBL] [Abstract][Full Text] [Related]
12. Somatrogon injection for the treatment of pediatric growth hormone deficiency with comparison to other LAGH products.
Velazquez EP; Miller BS; Yuen KCJ
Expert Rev Endocrinol Metab; 2024; 19(1):1-10. PubMed ID: 38112103
[TBL] [Abstract][Full Text] [Related]
13. The current state of long-acting growth hormone preparations for growth hormone therapy.
Yuen KCJ; Miller BS; Biller BMK
Curr Opin Endocrinol Diabetes Obes; 2018 Aug; 25(4):267-273. PubMed ID: 29746309
[TBL] [Abstract][Full Text] [Related]
14. Long-acting growth hormone in the treatment of growth hormone deficiency in children: a systematic literature review and network meta-analysis.
Zhu J; Yuan K; Rana S; Jakki SL; Bhat AS; Liang L; Wang C
Sci Rep; 2024 Apr; 14(1):8061. PubMed ID: 38580693
[TBL] [Abstract][Full Text] [Related]
15. Ten years with biosimilar rhGH in clinical practice in Sweden - experience from the prospective PATRO children and adult studies.
Lundberg E; Kriström B; Zouater H; Deleskog A; Höybye C
BMC Endocr Disord; 2020 Apr; 20(1):55. PubMed ID: 32349731
[TBL] [Abstract][Full Text] [Related]
16. Hormone replacement therapy in children: The use of growth hormone and IGF-I.
Pfäffle R
Best Pract Res Clin Endocrinol Metab; 2015 Jun; 29(3):339-52. PubMed ID: 26051295
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of efficacy and safety of long-acting PEGylated recombinant human growth hormone (Jintrolong) for patients with growth hormone deficiency.
Du H; Wu D; Yi P; Bai X; Luo Y; Yang H; Chen S; Pan H; Zhu H
J Pediatr Endocrinol Metab; 2022 Apr; 35(4):511-517. PubMed ID: 35245011
[TBL] [Abstract][Full Text] [Related]
18. Monitoring rhGH Safety: rhGH Registries, SAGhE and Future Needs.
Miller BS; Rosenfeld RG
Pediatr Endocrinol Rev; 2018 Sep; 16(Suppl 1):150-161. PubMed ID: 30378793
[TBL] [Abstract][Full Text] [Related]
19. Long-Acting Growth Hormone Preparations in the Treatment of Children.
Lal RA; Hoffman AR
Pediatr Endocrinol Rev; 2018 Sep; 16(Suppl 1):162-167. PubMed ID: 30378794
[TBL] [Abstract][Full Text] [Related]
20. Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation.
Bidlingmaier M; Biller BMK; Clemmons D; Jørgensen JOL; Nishioka H; Takahashi Y
Front Endocrinol (Lausanne); 2022; 13():1040046. PubMed ID: 36619571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
